Taysha Gene Therapies (TSHA) Change in Account Payables (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Change in Account Payables data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 39.65% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $213000.0 (up 103.56% YoY), and the FY2025 full-year result was -$153000.0, up 94.76% from the prior year.
• Change in Account Payables advanced to $1.3 million in Q1 2026, from -$2.1 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q1 2024 to a low of -$9.4 million in Q3 2022.
• A 5-year average of -$699000.0 and a median of -$1.2 million in 2023 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables jumped 31900.0% in 2022 and slumped 191.55% in 2024, its largest moves.
• Tracing TSHA's Change in Account Payables over 5 years: stood at -$4.6 million in 2022, then surged by 73.19% to -$1.2 million in 2023, then decreased by 22.28% to -$1.5 million in 2024, then plunged by 41.36% to -$2.1 million in 2025, then jumped by 160.63% to $1.3 million in 2026.
• Business Quant data shows TSHA's Change in Account Payables at $1.3 million in Q1 2026, -$2.1 million in Q4 2025, and -$1.9 million in Q3 2025.